The pattern of the pharmaceutical industry will see new changes, and a large number of pharmaceutical companies may be eliminated

By 2025, the pharmaceutical distribution industry will cultivate 1-3 large-scale digital and comprehensive pharmaceutical distribution enterprises with a value exceeding 500 billion yuan, 5-10 large-scale digital and comprehensive drug distribution enterprises with a value exceeding RMB 100 billion, and 5-10 specialized enterprises with a value exceeding RMB 50 billion.
Diversified pharmaceutical retail chain enterprises, about 100 intelligent, characteristic, and platform-based pharmaceutical supply chain service enterprises.
.
.
Recently the Ministry of Commerce issued the "Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry during the "14th Five-Year Plan" period", The opinions clearly put forward the requirements for increasing industry concentration
.
According to the requirements, leading companies will gain more market share, and the structure of the pharmaceutical circulation industry will be further optimized
.
Policy is the main motivation for the integration of large enterprises and the withdrawal of small and medium-sized enterprises from the historical stage
.
According to the industry, under the great changes in the pharmaceutical reform, not only the pharmaceutical business, but also many pharmaceutical industries, and even the careers of pharmaceutical practitioners are estimated to change and face new challenges
.
For example, with the release of the above-mentioned guidance, merger and integration will become the thematic direction of the development of the pharmaceutical business field in the next few years
.
In the pharmaceutical industry, with the implementation of volume procurement, the development pattern of the pharmaceutical industry will also usher in new changes
.
"There are more than 6,000 pharmaceutical companies in China.
With the normalization and institutionalization of centralized procurement, small and scattered companies will be eliminated in the future.
Large-scale, intensified, international, and innovative will be the development trend of the pharmaceutical industry
.
" Some people in the industry said so
.
For example, the “State Council’s Leading Group for Deepening the Reform of the Medical and Health System's Implementation Opinions on Deepening the Promotion of the Experience of Sanming City, Fujian Province and Deepening the Reform of the Medical and Health System” issued by the System Reform Department of the National Health Commission recently requires normalization and institutionalization of the national organization of drug consumables concentration belts.
We will gradually expand the scope of procurement, and strive to purchase more than 300 generic names for drugs by the end of 2022
.
At this stage, the fifth batch of national procurement has basically been implemented nationwide, and the sixth batch of national procurement (insulin special) has been reported
.
The normalization of volume procurement has become a foregone conclusion
.
According to the industry, according to the relevant situation of the selected enterprises in the past few rounds of national sourcing, it can be found that small and medium-sized enterprises that are unable to carry out consistency evaluation and do not meet the requirements of participating in national sourcing will gradually increase with the increase in the number of varieties that have undergone consistency evaluation, and more varieties will be included in the country.
And gradually lose the public hospital market
.
And those large domestic pharmaceutical companies that have funds for consistency evaluation, complete product lines, cost control capabilities, and stable product supply may become the main suppliers of nationally sourced products
.
As the saying goes, under the scouring of the tide, the big stones can still be strong, while the small sand stones may be hard to find
.
Volume procurement will continue to advance, and the impact of centralized procurement on the industry has already appeared
.
Those capable companies will not only become the main suppliers of nationally sourced varieties, but also transform into innovative drugs
.
Data shows that although most domestic pharmaceutical companies still focus on the production and sales of generic drugs, from the early low-level generic drugs, innovative drugs with both quality and reputation have emerged, which represents the clinical practice of Chinese pharmaceutical companies.
Breakthrough innovations in the testing and R&D pipeline
.
In addition, some analysts pointed out that the meaning of centralized procurement is not to pursue low prices, nor to deliberately pursue domestic substitution
.
It will be of great significance in improving the development quality of China's pharmaceutical industry, ensuring the safety and effectiveness of drugs, forcing pharmaceutical companies to innovate in products and management models, promoting the upgrading and structural adjustment of the pharmaceutical industry, and enhancing international competitiveness
.
In addition, some people said that from the situation of centralized procurement on-site competition, integration will be a general trend, and it is also an effective means to avoid vicious competition and the only way for enterprises to survive and develop
.